Please login to the form below

Not currently logged in
Email:
Password:

Tesaro

This page shows the latest Tesaro news and features for those working in and with pharma, biotech and healthcare.

Lynparza scores against pancreatic cancer

Lynparza scores against pancreatic cancer

approval would help AZ and MSD keep ahead of newer rivals in the class such as Tesaro's Zejula (niraparib) and Clovis' Rubraca (rucaparib).

Latest news

  • Advair generics and acquisitions to hit GSK in 2019 Advair generics and acquisitions to hit GSK in 2019

    acquisition of Tesaro and our new alliance with Merck KGaA that is expected to close in Q1 2019.". ... These are its BCMA targeting candidate in fourth-line multiple myeloma, and Tesaro’s Zejula for first line maintenance ovarian cancer and PD-1

  • GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

    In December, the firm entered the M&A market with the $5.1bn acquisition of cancer firm Tesaro, bringing with it PARP inhibitor Zejula and a pipeline including a PD-L1.

  • Pfizer takeover rumour ignites Amarin shares Pfizer takeover rumour ignites Amarin shares

    GlaxoSmithKline paid $5.1bn for Tesaro and its PARP inhibitor Zejula (niraparib) last month, and Eli Lilly snapping up Loxo Oncology for $8bn to claim its just-approved Vikrakvi (larotrectinib) for

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    That’s why Walmsley and her team decided to splash out $5.1bn on the acquisition of cancer specialist firm Tesaro last month, gaining with it the PARP inhibitor treatment Zejula. ... Along with Zejula, Tesaro also brings with it a pipeline PD-1

  • First-line ovarian approval cements AZ’s Lynparza lead First-line ovarian approval cements AZ’s Lynparza lead

    Lynparza is already well in front of its PARP inhibitor rivals, Tesaro’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib). ... Tesaro – in the process of being acquired by GlaxoSmithKline – is expecting phase 3 results in the same

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Jacob Plieth at Vantage recently highlighted this trend, with companies like Tesaro, Clovis Oncology and Acadia failing to meet revenue expectations for their new launches.

  • Deal Watch January 2018

    Licence. 339. TeneoBio/TESARO. Multi-specific antibodies for up to six undisclosed oncology targets using UniRat platform and discovery engine TeneoSeek.

  • Deal Watch February 2017 Deal Watch February 2017

    There has been speculation for several months that oncology company Tesaro may be the target for a large pharma bid and as a result its share price has increased by 570%

  • Deal Watch April 2016 Deal Watch April 2016

    Apart from the 3 deals by Abbvie, there were deals by GSK and Janssen with Zymeworks and Tesaro respectively. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for treatment of prostate cancer.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    350.5. AnaptysBio/ Tesaro. Collaboration, licence. mAbs to activate immune system response "checkpoints" - 3 targets: TIM-3, LAG-3 and PD-1 (preclinical).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics